Industry: Healthcare
Published Date: November-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 174
Report ID: PMRREP34946
The continuous renal replacement therapy market is estimated to increase from US$ 2.46 Bn in 2024 to US$ 2.79 Bn by 2031. The market is projected to record a considerable CAGR of 8.7% during the forecast period from 2024 to 2031.
Chronic kidney disease affects around 9.1% to 13.4% of the global population, highlighting the substantial demand for Continuous Renal Replacement Therapy (CRRT) solutions and driving the market forward. Innovations such as high-flux membranes and integration of artificial intelligence are enhancing the efficiency and safety of CRRT systems, contributing to market expansion.
Key Highlights of the Market
|
Market Attributes |
Key Insights |
|
Continuous Renal Replacement Therapy Market Size (2024E) |
US$ 2.46 Bn |
|
Projected Market Value (2031F) |
US$ 2.79 Bn |
|
Global Market Growth Rate (CAGR 2024 to 2031) |
8.7% |
|
Historical Market Growth Rate (CAGR 2019 to 2023) |
7% |
North America is set to lead the global continuous renal replacement therapy market, accumulating a share of 37% in 2024. A primary factor anticipated to drive growth in the region is the rising elderly population.
As the population diagnosed with renal problems in the region surges, alternative and superior procedures are being implemented with greater rigor. The increasing prevalence of sedentary lifestyles and poor dietary habits are regarded as the main catalyst for the escalation of different lifestyle-related illnesses, including renal failure, hypertension, and diabetes. For example,
The substantial presence of prominent key players in the region and increasing endorsement of CRRT products for various applications across countries are expected to drive demand. Also, government initiatives aimed at enhancing awareness of developments in renal therapy are likely to significantly contribute to broadening the market in North America.
|
Category |
Market Share in 2024 |
|
Product- Consumables |
62% |
Based on product, the market is divided into system and consumables, where the consumables category dominates the market. Surging use of charcoal filters, hemofilters, fluids, and other consumable items in Continuous Renal Replacement Therapy (CRRT) has contributed to the expansion of this category.
Hemofilters, commonly referred to as artificial kidneys, consist of a hollow fiber membrane that regulates the removal of solute and fluid. For patients with severe renal conditions, companies such as Baxter and Fresenius provide a range of consumables across various modalities. Despite their low cost, these products are often acquired more frequently than in other categories.
Due to an extraordinary surge in COVID-19 patients necessitating CRRT, companies experienced demand for various acute dialysis products up to five times greater than previous levels. Organizations persisted in collaborating with partners and governments globally to tackle these challenges. These helped in optimizing consumables like fluids and setting capacity as well as supply to accommodate skyrocketing demand for acute dialysis products in Europe and the U.S.
|
Category |
Market Share in 2024 |
|
Modality- Continuous Venovenous Hemofiltration (CVVH) |
32% |
Based on the modality, the market is segmented into Slow Continuous Ultra-Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF). Among these, the Continuous Venovenous Hemofiltration (CVVH) category dominates the market.
It is anticipated that the CVVH segment will rise as a result of the increasing cases of fluid overload situations. These are frequently seen in patients who have suffered acute renal injuries and are being treated in Intensive Care Units (ICUs).
Congestive heart failure was found to be responsible for around 5% of all-cause mortality among dialysis patients, according to reports published by Elsevier. The said condition is closely related to fluid overload, which will consequently lead to an increase in the requirement for and utilization of CVVH treatment. It is set to eventually aid growth of the market over the forecast period.
Continuous renal replacement treatment, also known as CRRT, is a cutting-edge medical treatment method intended for patients in severe conditions and experiencing acute kidney problems. Contrary to conventional intermittent hemodialysis, Continuous Renal Replacement Therapy (CRRT) allows for the continuous and gradual removal of waste products, excess fluids, and electrolytes from the bloodstream of the patient.
Individuals who may not be able to endure the rapid fluid shifts that are involved with conventional dialysis may benefit tremendously from this therapy. Utilizing a device that continually circulates a patient's blood through a specialized filter, a hemofilter or dialyzer, is an essential component of continuous blood recirculation (CRRT).
It is possible to remove fluid and toxins from the body in a progressive and controlled manner with the help of this filter. It is designed to replicate the normal functioning of the kidneys.
The Continuous Renal Replacement Treatment (CRRT) technique is frequently utilized in intensive care units to administer renal replacement therapy to patients who are hemodynamically unstable or critically ill. They often require a more delicate and persistent approach. This approach helps maintain fluid balance and electrolyte levels. It further contributes to the general stabilization of the patient's condition while allowing the kidneys to recuperate. A few leading companies are likely to adopt unique strategies to remain at the forefront of the industry. For instance,
The continuous renal replacement therapy market demonstrated steady growth during the historical period from 2019 to 2023 at a CAGR of 7%. It was driven by the increasing prevalence of Acute Kidney Injury (AKI) and the growing adoption of cutting-edge renal care solutions.
The demand was bolstered by rising cases of sepsis, hypertension, and diabetes, which are key risk factors for AKI. Key players focused on developing user-friendly and efficient CRRT devices, including hemofilters and bloodline set innovations.
Growth was prominent in North America and Europe due to well-established healthcare infrastructure and high awareness. Emerging markets in Asia Pacific began showing potential due to investments in healthcare?.
The CRRT industry is expected to accelerate over the forecast period, with developments in automation and artificial intelligence in dialysis machines to propel efficiency. An aging global population and rising critical care cases will likely amplify demand. Emerging regions, particularly Asia Pacific, are set to significantly surge due to expanding healthcare access and increased government funding.
Rapid development of pediatric-specific CRRT solutions and improved biocompatible filter materials are anticipated to fuel innovation. Partnerships and strategic expansions by leading players like Baxter and Fresenius will likely continue to shape the competitive landscape.
Increasing ICU Admissions to Drive Market Expansion
The constant rise in the number of patients hospitalized in acute and critical care units worldwide is a primary driver propelling the continuous renal replacement therapy market. Acute kidney damage is a prevalent complication in patients admitted to ICUs and is acknowledged as a significant global public health issue.
Such medication consistently has a significant effect on the care of critically ill patients. It is being administered exclusively in the intensive care unit for patients experiencing acute kidney injury resulting from various serious problems, including cancer, diabetes, and heart surgery. Depending on the patient's medical condition, it may be administered for 24 hours or an extended period.
Increasing geriatric population has also resulted in a rise in ICU admissions globally. The expanding elderly population is projected to surge the demand for the treatment and management of acute and chronic health disorders, including hypertension, cancer, heart disease, diabetes, and stroke. These conditions frequently necessitate intensive care, which are anticipated to augment the market size.
The growing senior population is expected to raise the incidence of ICU admissions, necessitating this therapy to address their health issues. All the aforementioned reasons are expected to drive market growth throughout the forecast period.
Availability of Customized CRRT Solutions to Bolster Demand
The swift progression of technology and the emergence of novel therapeutic products have enhanced the utilization of CRRT in the management of critically ill patients. To address the ever-changing demand for CRRT solutions, key players are concentrating on creating products designed for certain patient demographics, including pediatric patients.
Advancements in membrane technology and the customization of continuous renal replacement therapy, with other extracorporeal treatments, are anticipated to provide patient benefits. The application of data analytics in therapeutic administration, automated prescription processes, and the formulation of quality measures significantly enhances the quality of patient care, which is projected to enhance the market size. Several companies are coming up with new innovations to gain a competitive edge. For instance,
Stringent Regulatory Guidelines for CRRT Therapy Impeding Market Growth
Despite the significant potential of continuous renal replacement treatment for ICU patients in addressing acute kidney injury, tight regulatory guidelines for product production and approvals may hinder market expansion. Regulatory bodies worldwide, including the U.S. FDA, have established stringent rules for the production of CRRT products.
The rules are aimed at guaranteeing the provision of high-quality systems in critical and intensive care units for this therapy. Due to these severe regulatory criteria, various products that have received permission from other nations are yet to obtain approval from significant countries like the U.S.
The presence of rigorous restrictions, resulting in challenges to accessing these systems, is expected to impede market expansion throughout the forecast period. Compared to alternative renal replacement therapies, high expenses related to their installation and management are impeding market expansion.
Developments in Membrane Technology to Present New Opportunities
Membrane technology is a cornerstone of Continuous Renal Replacement Therapy (CRRT), as hemofilters are critical in removing waste, toxins, and excess fluids from the blood. Recent membrane design and material developments have significantly improved therapy efficiency, biocompatibility, and patient safety.
Similar to unique filters, high-flux membranes allow for more effective removal of larger molecules, such as inflammatory mediators, essential in critically ill patients with Acute Kidney Injury (AKI). Modern membranes are engineered for selective filtration, targeting specific toxins while preserving essential proteins and other vital blood components, minimizing side effects, and improving patient outcomes.?
The Continuous Renal Replacement Therapy (CRRT) industry is highly competitive, dominated by key players, including Baxter International Inc., Fresenius Medical Care AG, Medtronic, and Nikkiso Co., Ltd. These companies focus on product innovation, strategic acquisitions, and geographic expansion to strengthen their market position.
Baxter leads with its unique Prismaflex system, while Fresenius offers multiFiltratePRO, emphasizing customization and AI integration. Medtronic leverages data analytics for automation and precision in therapy.
Emerging players and regional firms are introducing cost-effective solutions, intensifying competition in price-sensitive markets, particularly Asia Pacific. Collaborations between healthcare providers and technology companies are also shaping the competitive landscape, fostering developments in biocompatible membranes and pediatric-specific CRRT systems?.
Recent Industry Developments in Continuous Renal Replacement Therapy Market
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2019 to 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled in the Report |
|
|
Report Coverage |
|
|
Customization and Pricing |
Available upon request |
By Product
By Modality
By End User
By Region
To know more about delivery timeline for this report Contact Sales
The global market is estimated to be valued at US$ 2.79 Bn in 2031.
CRRT procedure cost in India ranges from US$ 500 to US$ 700.
The average cost of CRRT machine is around US$ 24000 in 2024.
Per day cost of CRRT is estimated to be around US$ 850.
CRRT blood flow rates are typically 150ml/min.
